Many scooped up at 147
Possible next wave of short coming. 4:30pm.
Mkt always ahead and now pricing in worst viral scenario...and negative dow futures
guards80 ( Date: 24-Feb-2020 15:04) Posted:
|
Wah this one chui diao big time
just free falling now
Korea keep rise. Now 801cases 7death
Sgvale ( Date: 24-Feb-2020 15:02) Posted:
|
This one also tio virus already
FY result will either release on friday or Saturday.
Agree with you! Slow and steady 
Shortist waiting to short any counter that spike up. Best way is to go up bit by bit daily so they have no room to short.
guards80 ( Date: 24-Feb-2020 10:54) Posted:
|
My guess is because the situation in Asia (except S. Korea) is stabilising
guards80 ( Date: 24-Feb-2020 10:54) Posted:
|
Bec still accumulation mode?
guards80 ( Date: 24-Feb-2020 10:54) Posted:
|
all medical stock not much power also... not sure why.
The management did alot of shares buyback on may/june 2018.
Chiong ahh!!
China has changed the calculation of confirmed cases but outside China confirmed cases & death are worsening. From Korea to Italy to Iran. Very worrisome
Just a matter of time it will fly🚀
Sgvale ( Date: 22-Feb-2020 14:35) Posted:
|
SINGAPORE (Feb 5): Emerging areas of precision medicine could transform loss-making healthcare group Clearbridge Health into a ?potential unicorn in the making?, according to Tayrona Financial, the independent equity research house formerly known as NRA Capital.
?We see high growth potential for the company as doctors increasingly customise treatments to patients? genetic composition,? says analyst Liu Jinshu in a Jan 31 report. ?With its network across Asia, Clearbridge is positioning itself to tap on this trend over the next five to ten years.?
?With a stream of profitable acquisitions, we expect Clearbridge to turn EBITDA positive in 2020 and report its maiden profit in 2021,? Liu says. He notes that the company?s management has a track record of running and monetising medical technology businesses.
?We believe that Clearbridge deserves an aggressive valuation for its high future growth potential. Hence, we value Clearbridge at US$201.3 million,? Liu says. This translates to a fair value estimate of 41 cents .
?We see high growth potential for the company as doctors increasingly customise treatments to patients? genetic composition,? says analyst Liu Jinshu in a Jan 31 report. ?With its network across Asia, Clearbridge is positioning itself to tap on this trend over the next five to ten years.?
?With a stream of profitable acquisitions, we expect Clearbridge to turn EBITDA positive in 2020 and report its maiden profit in 2021,? Liu says. He notes that the company?s management has a track record of running and monetising medical technology businesses.
?We believe that Clearbridge deserves an aggressive valuation for its high future growth potential. Hence, we value Clearbridge at US$201.3 million,? Liu says. This translates to a fair value estimate of 41 cents .
I think they don like to wear mask, may damage their delicate skin !
What's wrong with South Korea. Sudden 200+ cases? Mini Wuhan ? Scary